Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for eczema sufferers with painful itchy nodules?

NCT ID NCT05451316

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug upadacitinib in people with moderate to severe atopic dermatitis (eczema) who also have prurigo nodularis, a condition causing intense itching and hard bumps. The goal was to see if the drug reduces itching and improves skin. The study was observational and took place in Japan, with participants taking upadacitinib daily for 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
upadacitinib (oral tablet)
What this could lead to
If successful, this could confirm that upadacitinib effectively reduces severe itching and nodules in people with atopic dermatitis and prurigo nodularis.
What could go wrong
This is a small, observational study with only one participant enrolled, so results may not apply to a broader population. Upadacitinib also carries risks like infections and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1 person

The number who actually took part.

Started

Dec 2022

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adolescents and adults, age ≥ 12 years, with a physician-confirmed diagnosis of atopic dermatitis (AD), who are prescribed UPA according to the label and practice in Japan. The decision to prescribe UPA will be made prior to and independent of study participation

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Physician confirmed diagnosis of moderate to severe atopic dermatitis (AD) at baseline * AD symptom onset \> 1 year prior to baseline * Initiation of UPA treatment for AD is indicated and prescribed per the label in Japan * Worst Pruritus Numerical Rating Scale (WP-NRS) ≥ 4 at baseline * Presence of palpable prurigo nodules at baseline Exclusion Criteria: * Prior treatment with UPA * Contraindications to UPA * Chronic pruritus resulting from another condition (e.g., neuropathic disorders) than AD, prurigo nodularis (PN) * PN caused by medication, metal allergy, infection, insect bite * Current participation in interventional research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Tohoku Medical and Pharmaceuti /ID# 252486

    Sendai, Miyagi, 983-0005, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.